All News
Improving Rheumatology Practice
How to best book patient appointments in rheumatology clinic? Should these be scheduled every 3 or 4 months regardless of patient status? Should they be scheduled by patient need or disease activity?
Read Article
RheumNow Podcast - Unwillingness to Change Therapy (11.19.21)
Surely you’ve seen this or been plagued by this patient, one that is not doing well, in need of a new regimen; you outline it, timeline it, define the side effects and send them off with a new prescription..
Read Article
Long Term Steroid Use in RA - Matters of the Heart: Dr. Mrinalini Dey ( @DrMiniDey) discusses abstract #1428 presented at the #ACR21 annual meeting.
https://t.co/E6RSlPAuRT https://t.co/QBhKD855aH
Links:
Dr. John Cush RheumNow ( View Tweet)
This podcast is devoted to discussing patient satisfaction and factors important in their willingness or unwillingness (resistance) to change therapies.
https://t.co/eVLlD8gEIM https://t.co/B24NWnGLHu
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Type 1 and Type II Lupus — Patient Perspectives: Dr. Mehta ( @bella_mehta) interviews Dr. Clowse about abstract #1277 presented at the #ACR21 annual meeting
https://t.co/2w1Lwwhplf https://t.co/4sJR6DG0q0
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: JAKi Safety: Dr. Aurelie Najm ( @AurelieRheumo) interviews Dr. Choy about JAKi safety data, including abstracts #0958, #1940 and #1941 presented at the #ACR21 annual meeting.
https://t.co/LOM8zz62Pm https://t.co/83HRCZdtfE
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Updates on New Treatments for SpA: Drs. Antoni Chan ( @synovialjoints) interviews Dr. Laura Coates discuss a number of studies related to new treatments for SpA presented at the #ACR21 annual meeting.
https://t.co/aCK1RRvTaW https://t.co/X1TlY88Jng
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Perspectives on CV safety: JAK inhibitor (Tofacitinib) and TNF inhibitors
https://t.co/g5FirIK9Af https://t.co/63s7IaKhl7
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Filgotinib (Jyseleca) was approved by European Commission approved for EU use in adults with moderately to severely active Ulcerative colitis (not responding to conventional therapy or a biologic). Rec based on Phase 2b/3 SELECTION trial. https://t.co/9VbCJse6Tr
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: An Old Friend – Methotrexate in Psoriatic Arthritis
Methotrexate (MTX) remains one of our most used and reliable tools against a variety of rheumatic diseases, particularly in the care of peripheral arthritis such as PsA.
https://t.co/kJdQ9Pd67v
#ACR21 @_Castillo_Pedro https://t.co/lpvZJaPcYd
Links:
Dr. John Cush RheumNow ( View Tweet)
Find all our #ACR21 podcast coverage here.
https://t.co/ZcWxysfoY1 https://t.co/mKOX4suJYi
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Drs. Jack Cush and the RheumNow Faculty Drs. David Liew, Swetha Ann Alexander, Meral El Ramahi, Mrinalini Dey and Robert Chao, discuss highlights from Day 2 at the #ACR21 meeting.
https://t.co/ZaXlhyEKwY
@drdavidliew @swethaann23 @MeralElRamahiMD @DrMiniDey @doctorRBC https://t.co/TNEJUEIRc4
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Emerging Therapies in Psoriatic Arthritis: Drs. Antoni Chan ( @synovialjoints) interviews Dr. FitzGerald about abstract #0490 and other PsA highlights being presented at the #ACR21 annual meeting.
https://t.co/1v8WhMkRHr https://t.co/UbqGkbupUM
Links:
Dr. John Cush RheumNow ( View Tweet)
This podcast is devoted to discussing patient satisfaction and factors important in their willingness or unwillingness (resistance) to change therapies.
https://t.co/QhjXkgW8f2 https://t.co/Zt8BxU0jVf
Links:
Dr. John Cush RheumNow ( View Tweet)
Geriatric Rheumatology:Improving care of aging patients
Dr.Kathryn Dao ( @KDAO2011) moderates a panel w/ Drs.Una Makris, Katherine Wysham, Sebastian Sattui + Devyani Misra, as they discuss aspects of improving care of/outcomes for aging patients. #ACR21
https://t.co/lF3yUZBEkd https://t.co/hYufA8ptqj
Links:
Dr. John Cush RheumNow ( View Tweet)
CBD and Opioids in Psoriatic Arthritis: Dr. Eric Ruderman ( @JointMD) reviews abstract #1456 and #1777 presented at the #ACR21 annual meeting.
https://t.co/QnjgjZ13Uq https://t.co/PdbMmcCoIH
Links:
Dr. John Cush RheumNow ( View Tweet)
Frailty in Lupus: Dr. Sheila Reyes ( @RHEUMarampa) reviews abstract #0869 presented at the #ACR21 annual meeting.
https://t.co/5jR74VQBeG https://t.co/AJIhR5Waip
Links:
Dr. John Cush RheumNow ( View Tweet)
Herpes Zoster and Rheumatoid Arthritis: Dr. Akhil Sood ( @AkhilSoodMD) reviews abstract #0981 presented at the #ACR21 annual meeting.
https://t.co/M95XQOBWVf https://t.co/X9vaAEAias
Links:
Dr. John Cush RheumNow ( View Tweet)
JAKi Safety: Dr. Aurelie Najm ( @AurelieRheumo) interviews Dr. Choy about JAKi safety data, including abstracts #0958, #1940 and #1941 presented at the #ACR21 annual meeting.
https://t.co/yZnM9ttDYv https://t.co/eKrocRZdbl
Links:
Dr. John Cush RheumNow ( View Tweet)
Type 1 and Type II Lupus — Patient Perspectives: Dr. Mehta ( @bella_mehta) interviews Dr. Clowse about abstract #1277 presented at the #ACR21 annual meeting
https://t.co/00ojx9rXut https://t.co/bO9chTneoV
Links:
Dr. John Cush RheumNow ( View Tweet)